RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

To evaluate the objective response rate (ORR) at 2  months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC).

Source: Cancer Imaging - December 9, 2019 Category: Radiology Authors: Olivier Lucidarme, Mathilde Wagner, Paul Gillard, Stefano Kim, Jean-Baptiste Bachet, Benoit Rousseau, Thibault Mazard, Christophe Louvet, Benoist Chibaudel, Romain Cohen, Marie-Line Garcia-Larnicol, Aurelien Gobert, Julie Henriques and Thierry Andr é Tags: Research article Source Type: research